Table 1.
Development of HCC in patients with cirrhosis on long-term antiviral therapy.
| Pt | Date startTx | Chang in Child Class On Tx | Date HCC Dx | Yrs on anti-HBV Tx at HCC DX | Yrs with HBV DNA (-) | Age (yr) at HCC Dx | Size (cm) and Site of HCC | HBVDNA at HCC Dx | Anti-HBV Tx | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4/1998 | B→A | 7/2007 | 9.3 | 3.4* | 53 | 1.1 Junction | UD# | LAM + TDF | alive |
| 2 | 6/2002 | A→A | 8/2007 | 5.2 | 4.7 | 70 | 1.0 Rt | UD | LAM + TDF | alive |
| 3 | 1/1998 | B→A | 3/2008 | 10.2 | 8.2 | 68 | 2.8 × 2.5 | UD | LAM + TDF | dead |
| 4 | 5/1998 | A→A | 2/2008 | 9.8 | 6.7 | 76 | 1.8 × 0.9 Lt | UD | LAM + TDF | alive |
| 5 | 7/2004 | B→B | 9/2009 | 5.2 | 4.7 | 52 | 3.9 Rt | UD | LAM + TDF | alive |
| 6 | 7/2001 | B→B | 9/2010 | 9.2 | 4.1 | 54 | 2.8 Rt | UD | LAM + TDF | dead |
| 7 | 2/2004 | A→A | 6/2013 | 9. 3 | 7.7 | 57 | 2.5 Lt med | UD | TDF | dead |
| 8 | 2/1996 | A→A | 7/2013 | 17.4 | 9.7 | 73 | 1.6 × 1.4 Rt | UD | TDF | dead |
| 9 | 8/1997 | A→A | 6/2014 | 16.8 | 5.9 | 54 | 2.2 × 1.9 Lt lat | UD | ETV | alive |
| 10 | 5/1996 | A→A | 10/2014 | 18.4 | 10.4 | 74 | 3.4 Rt | UD | LAM + TDF | dead |
| 11 | 2/2000 | A→A | 4/2015 | 15.2 | 12.4 | 62 | 3.4 × 3.4 Rt | UD | TDF | alive |
| 12 | 2/2000 | B→A | 5/2015 | 15.3 | 12.2 | 65 | 3.8 Rt | UD | TDF | alive |
LAM, lamivudine, TDF, Tenofovir disoproxil fumarate. UD#: undetectable. * pt has been HBV DNA (-) until 3 yrs before HBV DNA became detectable (22 IU/mL) when TDF was added.